FM-VP4 Forbes Medi-Tech

Current Opinion in Investigational Drugs

Volumn 4, Issue 9, 2003, Pages 1120-1125

  Burnett, John R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ASCORBIC ACID; CARDIOREX; CHOLESTEROL; DISODIUM ASCORBYLPHYTOSANYLPHOSPHATE; FCP 3P 4; FM VP 4; LIPID; PHYTOSTEROL; PLACEBO; UNCLASSIFIED DRUG;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MOLECULAR STRUCTURE; PHYTOSTEROLS; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0142245360     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. 368438 Forbes Medi-Tech Inc: Preliminary study results indicate exceptional cholesterol lowering capability of new pharmaceutical compound. Forbes Medi-Tech Inc Press Release 2000 May 25
2. 397459 Forbes provides Annual General Meeting update. Forbes Medi-Tech Inc Press Release 2001 January 30
3. 407081 Forbes Medi-Tech Inc announces CardioRex phase II clinical trial results. Forbes Medi-Tech Inc Press Release 2001 April 25
4. 407245 Forbes Medi-Tech Inc announces further FM-VP4 preclinical study results. Forbes Medi-Tech Inc Press Release 2001 April 26
5. 408923 Forbes Medi-Tech FM-VP4 pre-clinical study results presented to American Heart Association Conference. Forbes Medi-Tech Inc Press Release 2001 May 14
6. 418948 Forbes Medi-Tech and the University of British Columbia receive CIHR research grant to study cholesterol lowering sterol-based pharmaceuticals. Forbes Medi-Tech Inc Press Release 2001 August 13
7. 422883 Forbes Medi-Tech receives approval to initiate phase I/II clinical trial of cholesterol-lowering pharmaceutical FM-VP4. Forbes Medi-Tech Inc Press Release 2001 September 24
8. 433072 Effects of a novel hydrophilic phystanol analog plasma lipid concentrations in gerbils. Wasan KM, Najafi S, Peteherych KD, Pritchard PH J Pharm Sci 2001 90 11 1795-1799 Describes effects of acute FM-VP4 administration in gerbils on lipid lowering and body weight.
9. 434228 Phytostanol phosphoryl ascorbate, FM-VP4, decreases blood lipids and body weight without observed toxicity. Lukic T, Pritchard PH, Wasan KM Int Symp On Drugs Affect Lipid Metab 2001 September 9-12 108
10. 438148 Forbes Medi-Tech initiates phase I clinical trial of cholesterol-lowering pharmaceutical FM-VP4: Trial results expected in mid-2002. Forbes Medi-Tech Inc Press Release 2002 January 31
11. 438463 Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. Wasan KM, Najafi S, Wong J, Kwong M, Pritchard PH J Pharmacy Pharmaceutic Sci 2001 4 3 228-234 Describes the lipid lowering and body weight effects of chronic FM-VP4 administration in gerbils, as well as the lack of hepatic and renal toxicity.
12. 3H] cholesterol compared with controls, in a dose-dependent manner.
13. 445168 Forbes Medi-Tech provides update on operations. Forbes Medi-Tech Inc Press Release 2002 March 28
14. 450008 Forbes Medi-Tech announces record monthly revenues monthly phytosterol revenues increase by 50 per cent. Forbes Medi-Tech Inc Press Release 2002 April 30
15. 460643 Forbes Medi-Tech approved for phase II clinical trials. Forbes Medi-Tech Inc Press Release 2002 August 08
16. 472796 Forbes Medi-Tech provides status of pharmaceutical development and health claim status for phytosterols. Forbes Medi-Tech Inc Press Release 2002 December 04
17. 476796 Forbes Medi-Tech initiates dosing for phase II clinical trials on FM-VP4. Forbes Medi-Tech Inc Press Release 2003 January 20
18. 477315 Forbes Medi-Tech completes phase I safety study on FM-VP4. Forbes Medi-Tech Inc Press Release 2003 January 27
19. 491937 Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Lukic T, Wasan K, Zamfir D, Moghadasian MH, Pritchard P Metabolism 2003 52 4 425-431 This paper demonstrates that cholesterol reduction by FM-VP4 decreases atherosclerotic lesion formation in apoE knockout mice.
20. 491939 Influence of phytostanol phosphoryl ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. Wasan KM, Zamfir C, Pritchard PH, Pederson RA J Pharm Sci 2003 92 2 281-288 In a study of the effect of FM-VP4 on insulin resistance, hyperglycemia, plasma lipids and gastrointestinal absorption of exogenous cholesterol in Zucker fatty and lean rats, no alteration in glucose tolerance was observed in the non-diabetic, normoglycemic lead animals. However, a significant improvement in glucose tolerance was observed with FM-VP4 administration in fatty rats.
21. 491940 Effects of disodium ascorbyl phytostanol phosphates (FM-VP4) on cholesterol accumulation within rat intestinal cells. Wasan K, Yau E, Boulanger KD, Ramswamy M, Pritchard P AAPS PharmSci 2003 5 1 E6 Describes the in vitro inhibition by FM-VP4 on cholesterol accumulation in the rat intestinal cell line IEC-6; this inhibition is most effective at equimolar concentrations with cholesterol.
22. 491941 Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. Ramaswamy M, Yau E, Wasan K, Boulanger KD, Li M, Pritchard P J Pharmacy Pharmaceutic Sci 2002 5 1 29-38 Describes the in vitro effect of FM-VP4 on inhibiting cholesterol accumulation in the human colon cell line Caco2. This inhibition is independent of pancreatic lipase activity, P-gp activity or cholesterol incorporation in micelles.
23. 497029 Therapeutic potential of plant sterols and stanols. Plat J, Kerckhoffs DA, Mensink RP Curr Opin Lipidol 2000 11 6 571-576
24. 497030 Phytosterols in human nutrition. Ostlund RE Jr Annu Rev Nutr 2002 22 533-549
25. 497031 "Tall oil"-derived phytosterols reduce atherosclerosis in apoE-deficient mice. Moghadasian MH, McManus BM, Pritchard PH, Frohlich JJ Arterioscler Thromb Vasc Biol 1997 17 1 119-126
26. 497033 Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice. Volger OL, Mensink RP, Plat J, Hornstra G, Havekes LM, Princen HM Atherosclerosis 2001 157 2 375-381
27. 497034 Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: Clinical and experimental evidence. Moghadasian MH, Frohlich JJ Am J Med 199 107 6 588-594
28. 497038 Cholesterol-lowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low-fat foods. Eur J Clin Nutr 2002 55 12 1084-1090
29. 497040 Effects of plant sterols and stanols on lipid metabolism and cardiovascular risk. Plat J, Mensink BP Nutrition Metab Cardiovasc Diseases 2001 11 1 31-40